Academic Journal
Q1JAMA Neurology
About JAMA Neurology
JAMA Neurology is a scholarly journal published by American Medical Association. SCImago 2025 places it in Q1 with an SJR of 5.599 and an H-index of 298.
Its listed coverage is 2013-2026 and its research categories include Neurology (clinical) (Q1). The 2025 dataset reports 230 documents and 7157 citations across the latest three-year reporting window.
JAMA Neurology is a peer-reviewed medical journal published by the American Medical Association (AMA), recognized globally as a leading publication in the field of clinical neuroscience. With a strong focus on high-quality, evidence-based research, JAMA Neurology is a trusted source for neurologists, neuroscientists, and healthcare professionals seeking to stay updated on the latest advancements in neurology.
Founded in 1919 (originally as Archives of Neurology), JAMA Neurology has a long and prestigious history of publishing groundbreaking studies that shape the future of neurological care. Today, the journal is part of the JAMA Network, a collection of influential medical journals known for their rigorous peer-review standards, broad readership, and significant clinical impact.
Why JAMA Neurology Stands Out
1. High-Impact Research:
JAMA Neurology consistently ranks among the top neurology journals worldwide based on impact factor and citation metrics. The journal publishes original research, reviews, and opinion pieces covering all aspects of neurology—from neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease, to stroke, epilepsy, multiple sclerosis, neuroimmunology, and neuro-oncology.
2. Peer-Reviewed Excellence:
All articles in JAMA Neurology undergo a strict peer-review process conducted by leading experts in the field. This ensures that the research is not only scientifically sound but also clinically relevant, supporting evidence-based practice in neurology.
3. Global Reach and Accessibility:
As part of the JAMA Network, JAMA Neurology has a wide global readership. Its digital platform offers easy access to current and archived articles, podcasts, visual abstracts, and continuing medical education (CME) activities, making it a valuable resource for both clinical and academic professionals.
Key Features of JAMA Neurology
-
Original Research Articles: Cutting-edge studies offering new insights into diagnosis, treatment, and pathophysiology of neurological diseases.
-
Clinical Trials: Results from major clinical trials that influence treatment guidelines and patient care.
-
Review Articles: Comprehensive overviews of specific topics in neurology to inform clinical practice.
-
Opinion and Commentary: Expert perspectives on recent developments and controversies in neurological science.
-
Patient Pages and Infographics: Designed to help clinicians communicate complex neurological issues to patients.
Impact on the Field of Neurology
JAMA Neurology plays a crucial role in translating neuroscience discoveries into clinical practice. By publishing influential studies and encouraging dialogue among researchers and clinicians, the journal helps drive innovation in the diagnosis and treatment of neurological disorders. Many guidelines and clinical practices in neurology today are informed by research first published in this prestigious journal.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
JAMA Neurology is one of the world’s leading peer-reviewed medical journals dedicated to advancing the understanding, diagnosis, treatment, and prevention of neurological disorders. As part of the prestigious JAMA Network, JAMA Neurology publishes high-impact research and thought-provoking insights that shape the global landscape of neurology.
What is JAMA Neurology?
Launched in 1919 and rebranded under its current title in 2013, JAMA Neurology serves as a trusted platform for neurologists, neuroscientists, clinicians, and healthcare professionals. It is known for its rigorous peer-review process, commitment to scientific integrity, and clinical relevance.
The journal covers a wide spectrum of neurological topics including, but not limited to:
-
Alzheimer’s disease and other dementias
-
Stroke and cerebrovascular diseases
-
Epilepsy
-
Multiple sclerosis
-
Parkinson’s disease and movement disorders
-
Neuromuscular diseases
-
Neuroinfectious and autoimmune disorders
-
Pediatric neurology
-
Neurogenetics and neuroimaging
By focusing on both common and rare neurological conditions, JAMA Neurology bridges the gap between clinical practice and cutting-edge research.
Key Types of Content Published
JAMA Neurology publishes a diverse array of article types that cater to both researchers and clinicians. These include:
-
Original Investigations: Groundbreaking clinical trials, cohort studies, and epidemiological research.
-
Reviews: Comprehensive overviews on emerging trends and evolving treatment options.
-
Clinical Trials: Reports on newly developed therapies and interventions.
-
Viewpoints and Editorials: Expert commentary on contemporary neurological issues.
-
Case Reports and Clinical Challenges: Real-world cases that enhance diagnostic and clinical reasoning skills.
This broad scope ensures the journal remains relevant to all neurology subspecialties and medical professionals involved in neurological care.
Global Reach and Impact
With a high impact factor and global readership, JAMA Neurology is a top-ranked journal in the field. It attracts submissions from leading institutions worldwide and is indexed in major databases such as PubMed, Scopus, and Web of Science. The journal’s influence extends beyond academia to inform clinical guidelines, policy decisions, and patient care strategies.
Why JAMA Neurology Matters
As neurological disorders continue to rise globally—driven by aging populations and environmental factors—the importance of accurate, evidence-based information is more critical than ever. JAMA Neurology plays a vital role by disseminating research that improves early diagnosis, enhances treatment outcomes, and drives innovation in neurosciences.
For clinicians and researchers seeking authoritative information and a platform to share their work, JAMA Neurology remains an indispensable resource.
Recent Research Articles
Latest publications matched automatically by ISSN.
Treatment Discontinuation in MOGAD—One Size Does Not Fit All—Reply
Marine Boudot de la Motte, Antoine Gavoille, Romain Marignier
2026-08-31 · DOI: 10.1001/jamaneurol.2026.2939Amyloid-Targeting Treatments in Patients With Non–Alzheimer Disease Copathologies
Andy J. Liu, Suzanne E. Schindler, Heather Whitson
2026-08-31 · DOI: 10.1001/jamaneurol.2026.2933Tirofiban for Branch Atheromatous Disease–Related Stroke
Yicong Wang, Xiaoling Liao, Shuo Feng, Yuesong Pan et al.
2026-08-31 · DOI: 10.1001/jamaneurol.2026.2855Treatment Discontinuation in MOGAD—One Size Does Not Fit All
Su-Hyun Kim, Ho Jin Kim
2026-08-31 · DOI: 10.1001/jamaneurol.2026.2936Tirofiban for Branch Atheromatous Disease—End of the Line or New Opportunity?
Dixon Yang, S. Andrew Josephson, Hooman Kamel
2026-08-31 · DOI: 10.1001/jamaneurol.2026.2776Lifelong De Novo Aneurysm Risk After Aneurysmal Subarachnoid Hemorrhage in Young Survivors
Peter Alpkvist, Caroline Lindblad, Mikael Svensson
2026-08-24 · DOI: 10.1001/jamaneurol.2026.2830Conceptual Recognition of TDP-43–Associated Neurodegenerative Disease—Are We There Yet?
Mark A. Terrelonge, Peter T. Nelson, Ian R. Mackenzie
2026-08-24 · DOI: 10.1001/jamaneurol.2026.2811TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated Staging
Michael Benatar, Sami Barmada, Gregory A. Jicha, Clotilde Lagier-Tourenne et al.
2026-08-24 · DOI: 10.1001/jamaneurol.2026.2812A Call for Benzodiazepines in Airline Emergency Medical Kits
Joseph I. Sirven, Caden Collins, Adrian L. Rabinowicz, Enrique Carrazana et al.
2026-08-17 · DOI: 10.1001/jamaneurol.2026.2787Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy
Kai Michael Schubert, Carolina Ferreira-Atuesta, Arunachalam Soma, Johan Zelano et al.
2026-08-17 · DOI: 10.1001/jamaneurol.2026.2712Anti-CD320 Autoantibodies and Central Nervous System Vitamin B 12 Deficiency in Idiopathic Myelopathy
John V. Pluvinage, David Acero-Garces, Giacomo Greco, Carson E. Moseley et al.
2026-08-17 · DOI: 10.1001/jamaneurol.2026.2778Error in Title
2026-08-12 · DOI: 10.1001/jamaneurol.2026.3127Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial
Richard J. Nowak, Kimiaki Utsugisawa, Michael Benatar, Emma Ciafaloni et al.
2026-08-10 · DOI: 10.1001/jamaneurol.2026.2558Worsening Spastic Paraparesis After Lumbar Puncture in a Young Adult
Hui Sun, Lei Wu, Dehui Huang
2026-08-10 · DOI: 10.1001/jamaneurol.2026.2645Plasma Biomarkers for Neocortical Tau Burden
Guglielmo Di Molfetta, Wagner S. Brum, Ilaria Pola, Kübra Tan et al.
2026-08-10 · DOI: 10.1001/jamaneurol.2026.2650Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis
Maximilian Einsiedler, Sofia Sandgren, Sabine Schaedelin, Kiarra Ning et al.
2026-08-03 · DOI: 10.1001/jamaneurol.2026.2500Automated Speech Analysis to Identify Clinical, Anatomical, and Pathological Variants of Primary Progressive Aphasia
Jet M. J. Vonk, Giada Antonicelli, Siddarth Ramkrishnan, Salvatore Spina et al.
2026-08-03 · DOI: 10.1001/jamaneurol.2026.2520Multiple Sclerosis Onset Preceding Epstein-Barr Virus Infection
Dalia L. Rotstein, Colleen Maxwell, Helen Tremlett, Manav V. Vyas et al.
2026-08-03 · DOI: 10.1001/jamaneurol.2026.2514Global and Partial Cataplexy, Geste Antagoniste, and Startle Response in Narcolepsy Type 1
Roberta Di Giacomo, Lorella Pesce, Giuseppe Didato
2026-08-03 · DOI: 10.1001/jamaneurol.2026.2543Neurological Manifestations in Adult Survivors of Ebola Virus Disease
Bridgette Jeanne Billioux, Cavan Reilly, Collin van Ryn, Bryan Smith et al.
2026-08-01 · DOI: 10.1001/jamaneurol.2026.2112Reviews
Community Reviews
Version History
April 20, 2025 at 3:27 am
April 20, 2025